Free Trial
NASDAQ:LIPO

Lipella Pharmaceuticals Q1 2025 Earnings Report

Lipella Pharmaceuticals logo
$2.56 -0.15 (-5.57%)
Closing price 06/13/2025 03:58 PM Eastern
Extended Trading
$2.56 +0.00 (+0.04%)
As of 06/13/2025 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lipella Pharmaceuticals EPS Results

Actual EPS
-$0.64
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Lipella Pharmaceuticals Revenue Results

Actual Revenue
$0.13 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lipella Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
6:00PM ET

Earnings Documents

Lipella Pharmaceuticals Earnings Headlines

New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Lipella Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lipella Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lipella Pharmaceuticals and other key companies, straight to your email.

About Lipella Pharmaceuticals

Lipella Pharmaceuticals (NASDAQ:LIPO), a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

View Lipella Pharmaceuticals Profile

More Earnings Resources from MarketBeat